PeterGrantLurieMD

PubMed

• 1 citations
  Trials for second generation Covid-19 vaccines: Revisiting the debate over placebo use in developing country clinical trials.
  Peter Lurie> ;Indian Journal of Medical Ethics. 2021 Apr 1
• 5 citations
  Opioid exposure associated with poppy consumption reported to poison control centers and the U.S. Food and Drug Administration
  Eva Greenthal, Peter Lurie, Suzanne Doyon> ;Clinical Toxicology. 2021 Jan 12
• 1 citations
  Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
  James Heyward, Jennifer K. Chen, Kristin Meek, Peter Lurie, G. Caleb Alexander> ;Annals of Internal Medicine. 2020 Sep 29
• 20 citations
  Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
  James Heyward, Lily Olson, Joshua M. Sharfstein, Elizabeth A. Stuart, Peter Lurie, G. Caleb Alexander> ;JAMA Internal Medicine. 2020 Feb 1
• 1 citations
  Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017.
  Alexander C Egilman, Joshua D. Wallach, Christopher Morten, Peter Lurie, Joseph S. Ross> ;Research Integrity and Peer Review. 2019 Dec 9
• 3 citations
  Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration
  Harinder Singh Chahal, David Szeto, Anam H Chaudhry, Daniel W Sigelman, Stella Kim, Peter Lurie> ;JAMA Internal Medicine. 2019 Aug 1
• 11 citations
  Caffeinated energy drinks: adverse event reports to the US Food and Drug Administration and the National Poison Data System, 2008 to 2015.
  André O. Markon, Olivia E. Jones, Cecile Punzalan, Peter Lurie, Beverly J Wolpert> ;Public Health Nutrition. 2019 Jul 18
• 5 citations
  Harnessing the Power of Food Labels for Public Health
  Jennifer L. Pomeranz, Peter Lurie> ;American Journal of Preventive Medicine. 2019 Feb 20
• 31 citations
  Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products
  Jeffrey Eric Rollman, James Heyward, Lily Olson, Peter Lurie, Joshua M. Sharfstein, G. Caleb Alexander> ;JAMA. 2019 Feb 19
• 85 citations
  State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.
  Jing Xu, Corey S. Davis, Marisa Cruz, Peter Lurie> ;Drug and Alcohol Dependence. 2018 Aug 1
• 1 citations
  Suggestions for Improving Conflict of Interest Processes in the US Food and Drug Administration Advisory Committees-Past Imperfect.
  Peter Lurie> ;JAMA Internal Medicine. 2018 Jul 1
• 10 citations
  New Opioid Analgesic Approvals and Outpatient Utilization of Opioid Analgesics in the United States, 1997 through 2015.
  Grace Chai, Jing Xu, James Osterhout, Mark A. Liberatore, Kathleen L. Miller, Carolyn Wolff, Marisa Cruz, Peter Lurie, Gerald J. Dal Pan> ;Anesthesiology. 2018 May 1
• 3 citations
  Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment.
  Harinder Singh Chahal, Peter Capella, Ryan Presto, Jeffrey S. Murray, Martin Shimer, Mary Lou Valdez, Peter Lurie> ;BMJ Global Health. 2018 May 1
• 4 citations
  The US Food and Drug Administration's tentative approval process and the global fight against HIV.
  Harinder Singh Chahal, Jeffrey S. Murray, Martin Shimer, Peter Capella, Ryan Presto, Mary Lou Valdez, Peter Lurie> ;Journal of the International AIDS Society. 2017 Dec 1
• 25 citations
  How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
  Amy E. McKee, André O. Markon, Kirk M Chan-Tack, Peter Lurie> ;Journal of Clinical Pharmacology. 2017 Sep 15
• 9 citations
  Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.
  Marisa Cruz, Jing Xu, Mwango Kashoki, Peter Lurie> ;JAMA Internal Medicine. 2017 Aug 1
• 10 citations
  Association of Appearance of Conflicts of Interest With Voting Behavior at FDA Advisory Committee Meetings-A Cross-sectional Study.
  Jing Xu, Olubunmi Emenanjo, Michael Ortwerth, Peter Lurie> ;JAMA Internal Medicine. 2017 Jul 1
• 13 citations
  Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
  Christopher M. Jones, Pradip K. Muhuri, Peter Lurie> ;The Clinical Journal of Pain. 2017 May 1
• 48 citations
  Overview of FDA's Expanded Access Program for Investigational Drugs.
  Jonathan P. Jarow, Peter Lurie, Sarah Crowley Ikenberry, Steven Lemery> ;Therapeutic Innovation & Regulatory Science. 2017 Mar 1
• Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting.
  Jing Xu, Rajdeep Gill, Marisa Cruz, Judy A. Staffa, Peter Lurie> ;JAMA Pediatrics. 2016 Nov 1
• 98 citations
  Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing
  Christopher M. Jones, Peter Lurie, Douglas C. Throckmorton> ;JAMA Internal Medicine. 2016 Mar 1
• 5 citations
  US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs
  Tamy Kim, Peter Lurie, Richard Pazdur> ;Journal of Clinical Oncology. 2015 Aug 17
• 20 citations
  Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study
  Peter Lurie, Harinder Singh Chahal, Daniel W Sigelman, Sylvie Stacy, Joshua Sclar, Barbara Ddamulira> ;BMJ. 2015 Jun 10
• Preventing prescription opioid abuse--reply.
  Christopher M. Jones, Peter Lurie, Janet Woodcock> ;JAMA. 2015 Mar 10
• 28 citations
  Addressing Prescription Opioid Overdose: Data Support a Comprehensive Policy Approach
  Christopher M. Jones, Peter Lurie, Janet Woodcock> ;JAMA. 2014 Nov 5
• Join now to see all